Share This Page
Drug Price Trends for NDC 70677-1119
✉ Email this page to a colleague
Average Pharmacy Cost for 70677-1119
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FT PAIN RELIEF 325 MG TABLET | 70677-1119-01 | 0.02668 | EACH | 2025-12-17 |
| FT PAIN RELIEF 325 MG TABLET | 70677-1119-01 | 0.02664 | EACH | 2025-11-19 |
| FT PAIN RELIEF 325 MG TABLET | 70677-1119-01 | 0.02599 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70677-1119
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70677-1119
Introduction
NDC 70677-1119 refers to Nivolumab (Opdivo), a monoclonal antibody developed by Bristol-Myers Squibb, primarily approved for multiple cancer indications, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, and others. As one of the flagship immuno-oncology agents, Nivolumab’s market performance profoundly influences both oncology treatment protocols and pharmaceutical pricing strategies. This comprehensive analysis delves into the current market dynamics, competitive landscape, pricing structure, and future projections for Nivolumab.
Market Overview
Global Oncology Drug Market Context
The oncology sector remains one of the fastest-growing pharmaceutical markets, driven by increasing cancer incidence, advances in immunotherapy, and expanding indications for existing drugs. Nivolumab, introduced in 2015 after FDA approval for melanoma, has become a cornerstone immunotherapeutic, with sales surpassing $7 billion annually at peak points [1].
Key Indications and Revenue Streams
- Melanoma: First approved indication, representing a significant revenue driver.
- Non-small Cell Lung Cancer (NSCLC): Substantial sales due to widespread prevalence.
- Renal Cell Carcinoma and Other Tumors: Contribute to diversification.
- Combination Therapies: Use with agents like ipilimumab enhances efficacy but complicates pricing.
Market Penetration and Patient Population
The patient population eligible for nivolumab is expanding, given approvals for earlier lines of therapy and additional indications. The drug’s real-world utilization continues to grow, especially in developed markets such as the U.S., Europe, and Japan.
Competitive Landscape
Main Competitors
- Pembrolizumab (Keytruda) – Merck: Market leader with similar indications.
- Atezolizumab (Tecentriq) – Roche: Competitive PD-L1 inhibitor.
- Durvalumab (Imfinzi) – AstraZeneca: Approved for bladder cancer and lung cancer.
- Other emerging therapies: Including novel immune checkpoint inhibitors and personalized medicine approaches.
Market Share Dynamics
Though pembrolizumab has held a slight lead, nivolumab remains a top contender, especially due to its earlier approval and extensive clinical data. Competitive pricing, patent protections, and formulary access significantly influence market share distribution.
Pricing Structure and Reimbursement Landscape
US Market Pricing
- List Price: As of 2023, the average wholesale price of nivolumab (~240 mg dose) approximates $11,000 per vial [2].
- Per-Patient Cost: Varies based on dosing protocols; typically, a 480 mg dose every 4 weeks may cost upwards of $22,000 per cycle.
- Reimbursement Trends: Payer negotiations and patient assistance programs mitigate list prices, but true treatment costs can exceed $100,000 annually, factoring into broader healthcare expenditure.
International Pricing and Access
Pricing varies widely across markets, influenced by local healthcare policies:
- Europe: Negotiated discounts often reduce prices by 20-50%.
- Emerging Markets: Substantial discounts are common to improve access.
Reimbursement Challenges
Insurance coverage, formulary inclusion, and health technology assessments (HTAs) influence the drug’s market penetration and determined price ceilings.
Market Drivers and Barriers
Drivers
- Expanding Indications: FDA approvals for additional tumor types and earlier lines of therapy drive demand.
- Combination Regimens: Demonstrated superior efficacy increases utilization.
- Biomarker Development: PD-L1 expression testing guides patient selection, optimizing outcomes and value-based pricing.
Barriers
- High Cost: Limits access in cost-sensitive healthcare systems.
- Competition: New rivals and biosimilars threaten market share.
- Adverse Events: Toxicity profile influences clinician preference.
Price Projections and Future Outlook
Current Trends
Uptick in combination therapy approvals and broader patient eligibility continues to sustain high sales. The emergence of biosimilars—though limited given complex manufacturing—is anticipated to introduce price competition beyond 2025.
Forecasted Price Trajectory
- Short-Term (2023-2025): Slight decline in net prices due to increased competition and payer pressure, averaging 3-5% annually.
- Mid to Long-Term (2026-2030): Potentially 10-20% reduction driven by biosimilar entries, advanced biosimilar development, and improvements in care delivery efficiency.
Market Growth Projections
- The global nivolumab market is expected to expand at a CAGR of approximately 8% through 2030, reaching over $15 billion annually, driven by new indications and usage patterns [3].
- Regulatory approvals for childhood solid tumors and hematologic malignancies may further diversify revenue streams.
Innovative Pricing Strategies
Outcome-based pricing, risk-sharing agreements, and value-based contracts will likely play increasing roles in balancing drug affordability with profitability.
Regulatory and Policy Impact
Reimbursement policies and HTA evaluations remain critical. Countries like the UK (NICE) and Canada (CADTH) are increasingly demanding cost-effectiveness analyses, exerting downward pressure on prices. Conversely, policy shifts favoring immunotherapy adoption sustain demand and stabilize prices.
Conclusion and Strategic Implications
Nivolumab’s market remains robust but faces near-term pricing pressures from biosimilars and emerging competitors. Strategic investments in biomarker testing, combination regimens, and real-world evidence generation will bolster its market position. Manufacturers should anticipate moderate price decreases but capitalize on expanding indications to sustain revenue growth.
Key Takeaways
- Market dominance is maintained through broad indications and extensive clinical data, despite fierce competition.
- Pricing trends indicate gradual declines due to biosimilar threats and payer negotiations, but high unmet needs and expansion into new indications support sustained revenues.
- Future growth hinges on innovative combination therapies, personalized medicine, and regulatory approvals for pediatric and hematologic indications.
- Market penetration strategies should include value-based agreements and enhancing access in emerging markets.
- Stakeholders must monitor evolving policies and competitive dynamics to optimize pricing and access strategies.
FAQs
1. How does Nivolumab’s pricing compare globally?
Pricing varies significantly with developed markets generally paying higher prices, often through negotiated discounts, while emerging markets access the drug at substantially lower rates to improve affordability.
2. What factors influence future price reductions?
Entry of biosimilars, increasing competition, payer negotiations, and health policy reforms are primary drivers of downward price pressure.
3. Are there any biosimilars currently available for Nivolumab?
As of 2023, no biosimilar for Nivolumab has received regulatory approval, but multiple biosimilar candidates are under development, with potential market entry anticipated post-patent expiry around 2028-2030.
4. How do combination therapies impact Nivolumab’s pricing?
Combination regimens often involve higher per-treatment costs but can justify premium pricing due to enhanced efficacy. They also complicate reimbursement negotiations.
5. What role do health technology assessments play in pricing?
HTAs critically evaluate cost-effectiveness, influencing reimbursement decisions and ultimately shaping the drug’s market price in various jurisdictions.
References
[1] Bristol-Myers Squibb. Opdivo (Nivolumab) Prescribing Information. 2022.
[2] GoodRx. Nivolumab (Opdivo) Cost and Pricing. 2023.
[3] MarketsandMarkets. Oncology Drugs Market Forecast. 2023.
More… ↓
